Application of ELISA Technique and Human Microsomes in the Search for 11β-Hydroxysteroid Dehydrogenase Inhibitors

Daria Kupczyk, Renata Studzińska, Rafał Bilski, and Alina Woźniak

1Department of Medical Biology and Biochemistry, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Toruń, Poland
2Department of Organic Chemistry, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Toruń, Poland

Correspondence should be addressed to Rafał Bilski; rafal.bilski@cm.umk.pl

Received 7 January 2019; Accepted 2 May 2019; Published 12 May 2019

1. Introduction

Obesity is classified as a chronic metabolic disease. The frequency of cases of obesity is increasing especially in highly industrialized countries. It has been confirmed by many epidemiological researchers [1, 2]. Obesity is often accompanied by such phenomena as insulin resistance, dyslipidemias, disorders of carbohydrate metabolism, and hypertension. The phenomena listed above are the part of metabolic syndrome definition [3]. Obesity and overweight are the risk factors for the development of type II diabetes, metabolic syndrome, atherosclerosis, and cardiovascular diseases [4–8]. The main causes of the so-called simple obesity include incorrect nutrition, both qualitative and quantitative, as well as lack of physical activity. The genetic factors may also contribute to the development of simple obesity, although...
to a lesser extent. The causes of secondary obesity (which may occur in the course of central nervous system disorders, endocrinopathies, drug-induced syndrome due to the action of glucocorticosteroids, antidepressants, estrogens, or some neuroleptics) are more complex [9].

The metabolic syndrome mentioned earlier was first described in 1988 by Reaven [10]. It is recognized when carbohydrate metabolism, lipid disorders, and hypertension are coexisting, which leads to obesity and insulin resistance. Therefore, obesity, especially central, is an important element of the metabolic syndrome, because it is the main factor responsible for the development of insulin resistance [11]. In addition, abdominal obesity has the phenomenon of apparent hypercortisolism associated with excessive sensitivity of peripheral tissues to cortisol, although its blood level remains within the limits of reference values [12]. Hypercortisolism helps in the development of metabolic syndrome. Glucocorticoids, resulting in an increase in insulin resistance and accumulation of adipose tissue in the abdominal area, worsen the course of the metabolic syndrome [13].

Glucocorticoids belong to the group of steroid hormones secreted by the adrenal cortex. They are produced from cholesterol. Their secretion is controlled by the hypothalamic-pituitary-adrenocortical axis [14]. Corticosteroids and corticotropin are involved in the regulation of their secretion. Glucocorticoids play a regulatory role in the metabolism of proteins, lipids, and carbohydrates [15, 16]. In high concentrations, glucocorticoids may contribute to changes in the properties of biological membranes. Through the process of integration into the cellular and mitochondrial membranes, changes in the function of membrane proteins may occur and thus affect their permeability and enhance the processes of lipid peroxidation [17]. In the case of hypercortisolism, fat accumulates in the abdominal region, causing the development of the so-called abdominal obesity, which is one of the elements of the metabolic syndrome [18, 19]. The main glucocorticosteroids are cortisol (hydrocortisone) and corticosterone. In humans, the dominant glucocorticoid is cortisol. The biological activity of glucocorticoids determines the presence of the hydroxyl group in the C11 position of the steroid molecule and the oxidation of this group leads to the transformation of the compound into an inactive form. Therefore, both cortisol and corticosterone are biologically active steroids, while cortisone and 11-dehydrocorticosterone are inactive forms [20].

The most important factor that regulates the access of endogenous glucocorticoids to receptors, after release of glucocorticoids and their diffusion into the cytoplasm of target cells, is the steroid metabolism involving a microsomal enzyme, 11β-hydroxysteroid dehydrogenase (11β-HSD) (EC 1.1.1.146) [21]. It is an enzyme that catalyzes the transformation of cortisol and its inactive cortisone metabolite, corticosterone and 11-deoxycorticosterone. The first reaction occurs in humans, the second in rodents. The author of reports on this interconversion in 1953 was Amelung [22].

In humans, two isoforms of this enzyme have been identified, namely, type 1 (11β-HSD1) and type 2 (11β-HSD2), which are products of two different genes. The first type of enzyme is located on chromosome 1, while the second on chromosome 16 [23, 24]. These isoforms belong to the short-chain dehydrogenase super-family. They differ in terms of affinity for the substrate, direction of the catalyzed reactions, or substrate specificity [20]. They contain an N-terminal sequence that allows them to be anchored in the membrane of the endoplasmic reticulum (ER). The catalytic section of 11β-HSD1 is directed towards the ER light, whereas in the case of 11β-HSD2 towards the cytoplasm [25]. 11β-HSD1 dehydrogenase is found mainly in adipose tissue, liver, and lungs, whereas 11β-HSD2 is expressed in tissues associated with mineralocorticoid activity, namely, kidney, placenta, large intestine, and salivary glands. It converts cortisol into metabolically weak cortisone [26, 27], while the role of 11β-HSD1 is to convert cortisone to the active form of cortisol (Figure 1).

Inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity reduces cortisol levels, which may result in a decrease in fat mass, decrease in glucose levels in blood among patients with type 2 diabetes [28, 29], and lowering of total cholesterol level [30]. Therefore, from the therapeutic point of view, it is important to search new compounds that would be selective 11β-HSD1 inhibitors.

Previous reports show beneficial effects of reducing 11β-HSD1 activity, which is why attempts are being made to apply its inhibitors in the pharmacotherapy of civilization diseases. The first proposed blocker was arylsulfonamidothiazole, which in a nonselective manner inhibited 11β-HSD1. However, in studies conducted with mice, it was found that, despite lowering blood glucose, it did not increase peripheral glucose uptake [31, 32]. Similar results were achieved by the use of a nonspecific 11β-HSD1-carbenoxolone inhibitor in humans [33]. Currently, compounds are being sought that would selectively inhibit the activity of the enzyme, and their effect would be to reduce body weight, lower triglycerides, total cholesterol, and insulin, or prevent atherosclerotic plaque formation.

2. Materials and Methods

2.1. Reagents. The reagents were bought commercially and used without further purification: 18-beta-glycyrrhetinic acid from AcrOs Organic, phosphate buffer powder, cortisone, NADPH tetrasodium salt from Sigma-Aldrich, dimethylsulfoxide from POCh Poland, carbenoxolone (sodium salt) from Cayman Chemical Company, pooled human liver microsomes, mixed gender (1mL, 20 mg/mL Lot No. 140013 XenoTech), Cortisol Elisa Ref Dk0001 n Lot No. 4297 DiaMera, ELISA Kit for 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Lot No. L160706125 Cloud-Clone Corp., Human Kidney Microsomes, mixed gender (0.5 mL, 10 mg/mL Lot No. 160088 XenoTech), Enzyme-Linked Immunosorbent Assay (ELISA) Kit for 11-Beta-Hydroxysteroid Dehydrogenase Type 2 Lot No. L1707221781, Cloud-Clone Corp., PBS Lot No. H16008 Pan Biotech.

2.2. Preparation of the Compounds 1 - 7 [34–36]. The compounds 1 - 6 used in determination of 11β-hydroxysteroid dehydrogenase inhibition were synthesized earlier. The compounds were synthesized, respectively: 1 and 4 according
to [34], the compounds 2 and 3 according to [35], and the compounds 5 and 6 according to [37]. The compound 7 (carbenoxolone) was purchased commercially from Cayman Chemical Company.

2.3. Determination of 11β-HSD1 Activity in Human Liver Microsomal Fractions. The enzyme assay was performed using a microtest plate with 96 wells coated with the 11β-hydroxysteroid type 1 dehydrogenase specific antibody. The manufacturer’s instruction (Cloud–Clone Corp. SEC268Hu) was used as a guidance to perform the method. As the material for this study, the microsomal fraction of human liver at 20 mg/mL supplied from XenoTech was used. The activity of 11β-HSD1 was determined with 4 microsomal concentrations (1 μL/mL, 2.5 μL/mL, 5 μL/mL, and 10 μL/mL) from three independent determinations.

2.4. The Reduction Reaction of Cortisone to Cortisol. The reduction reaction of cortisone to cortisol was carried out on 96-well microplate in the presence of the enzyme 11β-HSD1 in a total volume of 100 μL: for this purpose, 20 μL of a cortisone/NADPH mixture with a final concentration of 200 nM/2 mM, 10 μL of microsomes (1.13 μg/mL 11β-HSD1) solution in PBS to obtain the final quantity of 2.5 μg, 60 μL phosphate buffer pH 7.4, and 10 μL of the appropriate inhibitor solution prepared in a DMSO/water system in a ratio of 1/99 with a final concentration of 10 μM. The microplate prepared in this way was incubated for 150 minutes at 37°C. During the incubation an orbital shaker was used. After the incubation was complete, the reaction was stopped by adding 10 μL of a solution that contained 100 μM of 18β-glycyrrhetinic acid in PBS.

2.5. Determination of 11β-HSD1 Inhibition. The quantity of cortisol formed from cortisone in the reaction described in Section 2.4 was determined using a cortisol ELISA kit DiaMtra. For this purpose, from each well in which the reduction reaction of cortisone was carried out (see Section 2.4), 10 μL of the reaction mixture was taken and placed in a corresponding place on a 96-well microplate. The method was carried out in accordance with the manufacturer’s instructions (Cortisol Elisa Ref Dk0001n Lot No. 4297 DiaMtra). The concentration of the obtained cortisol in the analyzed samples was obtained using the standard curve. The percent of 11β-HSD1 inhibition was determined in relation to the zero-sample (a sample in which 10 μL of DMSO/H2O 1/99 solution was added instead of the inhibitor’s solution).

2.6. Determination of 11β-HSD2 Activity in Human Kidney Microsomal Fractions. The enzyme assay was performed using a microplate with 96 wells coated with the 11β-hydroxysteroid type 2 dehydrogenase specific antibody. The method was carried out according to the manufacturer’s instructions (Cloud–Clone Corp. SEF183Hu). The microsomal fraction of human kidney at 10 mg/mL supplied from XenoTech was used as the material for the study. The activity of 11β-HSD2 was determined with 4 microsomal concentrations (1 μL/mL, 2.5 μL/mL, 5 μL/mL, and 10 μL/mL) from three independent determinations.

2.7. The Oxidation Reaction of Cortisol to Cortisone. The oxidation reaction of cortisol to cortisone was carried out on 96-well microplates in the presence of the enzyme 11β-HSD2 in a total volume of 100 μL: for this purpose, 20 μL of a cortisol/NAD mixture with a final concentration of 200 nM/2 mM, 10 μL of microsomes (0.39 μg/mL 11β-HSD1) solution in PBS to obtain the final quantity of 2.5 μg, 60 μL phosphate buffer pH 7.4, and 10 μL of the appropriate inhibitor solution prepared in a DMSO/water system in a ratio of 1/99 with a final concentration of 10 μM. The microplates prepared in this way were incubated for 150 minutes at 37°C. During the incubation, an orbital shaker was used. After the incubation was complete, the reaction was stopped by adding 10 μL of a solution that contained 100 μM of carbenoxolone in PBS.

2.8. Determination of 11β-HSD2 Inhibition. The quantity of unreacted cortisol (in the reaction described in Section 2.7) was determined using a cortisol ELISA kit DiaMtra. For this purpose, from each well in which the oxidation reaction of cortisol was performed (see Section 2.7), 10 μL of the reaction mixture was taken and placed in a suitable place on a 96-well plate. The method was performed in accordance with the manufacturer’s instructions (Cortisol Elisa Ref Dk0001n Lot No. 4297 DiaMtra). The concentration of the unreacted cortisol in the analyzed samples was obtained using the standard curve. The percent of 11β-HSD2 inhibition was determined in relation to the zero-sample (a sample in which 10 μL of DMSO/H2O 1/99 solution was added instead of the inhibitor’s solution).
3. Results and Discussion

Currently conducted research’s results show beneficial effects of the reduction of 11β-HSD1 activity and, due to this fact, attempts are being made to apply its inhibitors in the pharmacotherapy of civilization diseases. In the search for effective and selective 11β-HSD1 inhibitors in recent years, attention has been paid to (1,3-benzothiazol-2-yl) benzene sulfonamides [37], adamantyl amides [38], thiazolo[3,2-a]pyrimidine-5-one derivatives [39], and thiazole derivatives (including BVT-14225, BVT-2733, and BVT-3498) [31, 40, 41].

In this group of compounds, Biovitrum BVT-3498 deserves particular attention (Figure 2). In spite of the fact that carbenoxolone also has an inhibitory effect on 11β-HSD2, it has undergone clinical trials and successfully completed the second phase of research in 2002. However, in 2005, research for unexplained reasons was suspended [42].

Highly selective 11β-HSD1 inhibitors were found to be 2-aminothiazol-4(5H)-one derivatives, e.g., Amgen 2922 and AMG-221 (BVT-83370) (Figure 2) [42–45]. AMG-221 (BVT-83370) has successfully passed the phase I of clinical trials. This association has been studied on the obese group and despite good prognosis (IC$_{50}$ = 0.975 ng/mL and maximum extent of enzyme inhibition in adipose tissues of I$_{max}$ = 1.19 ng/mL) in 2011, the study on the implementation of this compound as a drug was cancelled. Therefore, substances that would selectively inhibit 11β-hydroxysteroid dehydrogenase type 1 are still being sought.

In order to preestimate the applicability of the compounds as 11β-HSD1 inhibitors, it is necessary to develop a rapid, effective, and relatively inexpensive method to determine the inhibition of this enzyme. Previous studies on 11β-HSD inhibition were mainly based on scintillation proximity assay (SPA) [40, 43, 46]. The purified enzyme [43] or whole cells (CHO cell line stably overexpressing human or mouse 11β-HSD1 [43], Chinese hamster ovary cells stably transfected with human 11b-HSD1 [46], and human embryonic kidney cell cultures (HEK293) cell-based assay [40]) were used to perform the necessary reactions.

We decided to develop a fast, easy, and relatively cheap method of determination of inhibiting both enzyme isoforms in order to be able to carry out the rapid screening of the synthesized compounds in this direction. For this purpose, to avoid the multiplication of cells containing the desired dehydrogenase isoform, as well as the proper preparation of pure enzyme for the reaction, we decided to use commercially available microsomal fractions. Determination of 11β-HSD1 in human liver microsomal fractions and 11β-HSD2 in human kidney microsomal fractions showed that they contain an amount of enzyme sufficient to affect the conversion of cortisone to cortisol and inversely. The advantage of microsomes is that they do not require time-consuming preparation and can be used immediately after dilution in PBS.

After the reduction reaction of cortisone using human liver microsomal fractions, in order to determine whether test compounds inhibit the activity of 11β-HSD1, the amount of obtained cortisol was determined by ELISA using cortisol ELISA kit DiaMetra. It is also a quick technique that allows the determination of cortisol levels in many samples simultaneously.

In order to verify the correctness of the method developed in our study, we have tested the inhibition of 11β-HSD1 by carbenoxolone—a known inhibitor of this enzyme. For comparison, compounds that theoretically should not inhibit 11β-HSD1 activity were also used in the study. We focused our attention on N-allyl-2-thiouracil derivatives (Table 1). These compounds are obtained by reacting N-allylthioureia with the corresponding β-oxoesters or their acetals in a basic or acidic medium [34–36] (Figure 3).

Before checking the method, compounds 1 - 6 were analyzed using the PASS online program. PASS (Prediction of Activity Spectra for Substances) is a software product
Figure 3: Synthesis of thiouracil derivatives 1 – 6.

designed as a tool for evaluating the general biological potential of an organic drug-like molecule. PASS provides simultaneous predictions of many types of biological activity based on the structure of organic compounds. Thus, it can be used to estimate the biological activity profiles for virtual molecules, prior to their chemical synthesis and biological testing [47]. The use of PASS online software consists in presenting the structural formula of the compound we are interested in. The software compares the structure of a given compound with compounds of known biological activity found in the database. On this basis, it estimates the likelihood of the activity of a given compound in a specific direction. We use the PASS online program to design compounds that would have specific biological activity of interest to us. We also used it in the design of molecules that would show inhibitory activity towards 11β-HSD1 [41]. In this way, we received compounds whose activity provided by the PASS online program was confirmed in in vitro tests.

There are many possible biological effects of these compounds; however, for none of them, the PASS program does not predict activity towards inhibition of 11β-hydroxysteroid dehydrogenase. Unexpectedly, it turned out that these compounds inhibit the enzyme activity to a small extent (from 8.82 to 39.71% at an inhibitor concentration of 10 μM). Such a low percentage of inhibition at such high concentration of inhibitor gives these compounds no practical use as 11β-HSD1 inhibitors. However, such large differences in the inhibition of enzyme activity between the known inhibitor, carbenoxolone, and potentially inactive compounds confirm the effectiveness of the method developed by us.

The fact that 3-N-allyl-2-thiouracil derivatives, although PASS does not show the probability of inhibiting 11β-HSD1, inhibit the activity of this enzyme makes it worth looking at this group of compounds in the search for new 11β-HSD1 inhibitors. There is a chance that a slight modification of the structure (e.g., introduction of other substituents to the pyrimidine ring) will increase the activity of compounds.

The effectiveness of our method of determining 11β-HSD1 inhibition using human liver microsomal fractions and ELISA technique prompted us to carry out analogous tests to determine the inhibition of the enzyme isoform 2. For this purpose, the human kidney microsomes containing 11β-HSD2 were used. In their presence, the cortisol oxidation reaction was carried out. To determine the degree of inhibition of 11β-HSD2 we decided to use the same ELISA kit that we used in the case of the reverse reaction. This time we determined the concentration of unreacted cortisol, which allowed us to calculate the concentration of cortisone in postreaction mixtures and consequently to calculate the % inhibition of 11β-HSD2 by the inhibitor. Assays for inhibition
Table 1: N-allyl-2-thiouracil derivatives.

| No. | M.p. of 1–6 /lit. M.p. (°C) | % of inhibition 11β-HSD1 10μM1 | % of inhibition 11β-HSD2 10μM1 |
|-----|-----------------------------|-------------------------------|-------------------------------|
| 1.  | 192.5-194 /193.5-194.5 [34] | 8.82±0.86                    | 28.08±1.02                   |
| 2.  | 153-154 / 154.5-155 [35]   | 30.88±1.29                   | 19.18±1.45                   |
| 3.  | 204-205.5 /201-203.5 [35]   | 35.29±2.01                   | 37.33±2.03                   |
| 4.  | 176-177.5 /177.5-179.5 [34] | 39.71±1.94                   | 24.66±2.09                   |
| 5.  | 121-122 / 119.5-121 [36]    | 30.88±1.53                   | 16.78±1.24                   |
| 6.  | 188-189.5 / 189-191 [36]    | 38.24±1.85                   | 23.29±1.35                   |
| 7.  | carbenoxolone                | -                            | 89.70±3.45                   | 15.06±2.06                   |
| 8.  | 18β-glycyrrhritic acid       | -                            | 88.24±2.05                   | 10.96±3.01                   |

1The inhibition of 11β-HSD1 and 11β-HSD2 was determined with inhibitors concentration 10 μM from three independent determinations.

of 11β-HSD2 were conducted for two known inhibitors: carbenoxolone (15.06% at a concentration of 10 μM) and 18β-glycyrrhetinic acid (10.96% at a concentration of 10 μM).

4. Conclusion

In conclusion, we used ELISA technique using 96-well microplates as a method that can quickly and efficiently measure the inhibition of both 11β-HSD1 and 11β-HSD2. This method can be used to search for and determine inhibitors of this enzyme. Another advantage of using this technique is the relatively inexpensive cost of the measurement. In the diagnostic and therapeutic process, there is a constant need to provide and improve therapeutic agents. Hence in our study these tests have been undertaken. Furthermore 3-N-allyl-2-thiouracil derivatives, although due to their structure have
not previously been considered as potential inhibitors of 11β-HSD1, are a group worth considering, because by modifying their structure (e.g., by introducing other substituents into the pyrimidine ring) it will be possible to obtain an increase in the activity of compounds in this regard.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

[1] W. P. T. James, “The epidemiology of obesity: the size of the problem,” Journal of Internal Medicine, vol. 263, no. 4, pp. 336–352, 2008.

[2] WHO, “Obesity and overweight,” http://www.who.int/mediacentre/factsheets/, 2009.

[3] D. J. Magliano, J. E. Shaw, and P. Z. Zimmet, “How to best define the metabolic syndrome,” Annals of Medicine, vol. 38, no. 1, pp. 34–41, 2006.

[4] R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, “The metabolic syndrome,” The Lancet, vol. 365, no. 9468, pp. 1415–1428, 2005.

[5] S. Cook, M. Weitzman, P. Auinger, M. Nguyen, and W. H. Dietz, “Prevalence of a metabolic syndrome phenotype in adolescents: findings from the Third National Health and Nutrition Examination Survey, 1988–1994,” JAMA Pediatrics, vol. 157, no. 8, pp. 821–827, 2003.

[6] E. Malecka-Tendera, É. Erhardt, and D. Molnár, “Type 2 diabetes mellitus in European children and adolescents,” Acta Paediatrica, vol. 94, no. 5, pp. 543–546, 2005.

[7] E. A. Oga and O. R. Eseyin, “The obesity paradox and heart failure: a systematic review of a decade of evidence,” Journal of Obesity, vol. 2016, 9 pages, 2016.

[8] O. Osei-Yeboah, W. K. B. A. Owiredu, G. K. Norgbe et al., “The prevalence of metabolic syndrome and its components among people with type 2 diabetes in the ho municipality, Ghana: a cross-sectional study,” International Journal of Chronic Diseases, vol. 2017, Article ID 8765804, 8 pages, 2017.

[9] L. I. Bujańska, S. Kumar, and P. M. Stewart, “Does central obesity reflect Cushing’s disease of the omentum?” The Lancet, vol. 349, no. 9060, pp. 1210–1213, 1997.

[10] M. G. Reaven, “Role of insulin resistance in human disease,” Diabetologia, vol. 37, no. 12, pp. 1995–1947, 1988.

[11] L. A. Moreno, I. Pineda, G. Rodriguez, J. Fleta, A. Sarria, and M. Bueno, “Waist circumference for the screening of the metabolic syndrome in children,” Acta Paediatrica, vol. 91, no. 12, pp. 1307–1312, 2002.

[12] P. Björntorp and R. Rosmond, “Obesity and cortisol,” Nutrition Journal, vol. 16, no. 10, pp. 924–936, 2000.

[13] T. Miazgowski, “Otylosc a cukrzycy,” Family Medicine & Primary Care Review, vol. 14, no. 3, pp. 462–467, 2012.

[14] A. Vegiopoulos and S. Herzig, “Glucocorticoids, metabolism and metabolic diseases,” Molecular and Cellular Endocrinology, vol. 275, no. 1-2, pp. 43–61, 2007.

[15] D. H. van Raalte, D. M. Ouwens, and M. Diamant, “Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?” European Journal of Clinical Investigation, vol. 39, no. 2, pp. 81–93, 2009.

[16] J. C. Buckingham, “Glucocorticoids: Exemplars of multi-tasking,” British Journal of Pharmacology, vol. 147, no. 1, pp. S258–S268, 2006.

[17] C. Stahn and F. Buttgereit, “Genomic and nongenomic effects of glucocorticoids,” Nature Clinical Practice Rheumatology, vol. 4, no. 10, pp. 525–533, 2008.

[18] P. Anagnostis, V. G. Athyros, K. Tsialonas, A. Karagiannis, and D. P. Mikhailidis, “The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 8, pp. 2692–2701, 2009.

[19] P. L. Huang, “A comprehensive definition for metabolic syndrome,” Disease Models & Mechanisms, vol. 2, no. 5-6, pp. 231–237, 2009.

[20] N. Draper and P. M. Stewart, “11ß-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action,” Journal of Endocrinology, vol. 186, no. 2, pp. 251–271, 2005.

[21] A. Nagalski and A. Kiersztan, “Fizjologia i molekularny mechanizm działania glikokortykoidów,” Postepy Higieny i Medycyny Doświadczalnej, vol. 64, pp. 133–145, 2010.

[22] M. Szopa and M. Wamil, “Inhibitor dehydrogenazy 11beta-hydrostroteroidowej: nowy cel w farmakoterapii zespołu metabolicznego,” Diabetologia Praktyczna, vol. 8, no. 3, pp. 77–83, 2007.

[23] G. M. Tannin, A. K. Agarwal, C. Monder, M. I. New, and P. C. White, “The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization,” Journal of Biological Chemistry, vol. 266, pp. 16653–16658, 1991.

[24] Z. Kroczowski, K. X. Li, and K. Koyama, “The type I and type II 11beta-hydroxysteroid dehydrogenase enzymes,” Journal of Steroid Biochemistry and Molecular Biology, vol. 69, pp. 391–401, 1999.

[25] M. Wamil and J. R. Seckl, “Inhibition of 11ß-hydroxysteroid dehydrogenase type I as a promising therapeutic target,” Drug Discovery Therapy, vol. 12, no. 13-14, pp. 504–520, 2007.

[26] P. M. Stewart and Z. S. Krozowski, “11 Beta-hydroxysteroid dehydrogenase,” Vitam Horm, vol. 57, pp. 249–324, 1999.

[27] S. Dias, S. Paredes, and L. Ribeiro, “Drugs involved in dyslipidemia and obesity treatment: focus on adipose tissue,” International Journal of Endocrinology, vol. 2018, 21 pages, 2018.

[28] T. Böhme, C. K. Engel, G. Farjot et al., “1,1-Dixo-5,6-dihydro-[4,1,2]oxathiazines, a novel class of 11ß-HSD1 inhibitors for the treatment of diabetes,” Bioorganic & Medicinal Chemistry Letters, vol. 23, no. 16, pp. 4685–4691, 2013.

[29] A. Anderson and B. R. Walker, “11ß-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease,” Drugs, vol. 73, no. 13, pp. 1385–1393, 2013.

[30] R. C. Andrews, O. Rooyackers, and B. R. Walker, “Effects of the 11ß-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 1, pp. 285–291, 2003.

[31] T. Barf, J. Vallgård, R. Emond et al., “Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. discovery of potent and selective inhibitors of the 11ß-hydroxysteroid dehydrogenase type I,” Journal of Medicinal Chemistry, vol. 45, no. 18, pp. 3813–3815, 2002.
[32] P. Alberts, C. Nilsson, G. Selen et al., “Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains,” Endocrinology, vol. 144, no. 11, pp. 4755–4762, 2003.

[33] B. R. Walker, A. A. Connacher, R. M. Lindsay, D. J. Webb, and C. R. W. Edwards, “Carbenoxolone increases hepatic insulin sensitivity in man: A novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation,” The Journal of Clinical Endocrinology & Metabolism, vol. 80, no. 11, pp. 3155–3159, 1995.

[34] K. Turski and M. Draminski, “Synthesis of 3-N-allyl-6-alkyl-2-thiouracils,” Polish Journal of Chemistry, vol. 66, Article ID 15911596, 1992.

[35] K. Turski and M. Draminski, “Possibilities of synthesizing 3-N-Alkyl derivatives of 2-Thiouracils under basic and acidic condensation conditions. selective synthesis of new 3-N-Allyl-5,6-dialkyl-2-thiouracils,” Polish Journal of Chemistry, vol. 67, pp. 1973–1979, 1993.

[36] M. Draminski, K. Turski, Y. Tateoka et al., "Synthesis and sedative-hypnotic effects of N3-Allyl- and N1-Allyl-5,6-substituted 2-Thiouracil derivatives in mice," Chemical & Pharmaceutical Bulletin, vol. 46, no. 9, pp. 1370–1373, 1998.

[37] H. Moreno-Díaz, R. Villalobos-Molina, R. Ortiz-Andrade et al., “Antidiabetic activity of N-(6-substituted-1,3-benzothiazol-2-yl)benzenesulfonamides,” Bioorganic & Medicinal Chemistry Letters, vol. 18, no. 9, pp. 2871–2877, 2008.

[38] K. S. Gudmundsson and B. A. Johns, “Imidazo[1,2-a]pyridines with potent activity against herpesviruses,” Bioorganic Medicinal Chemistry Letters, vol. 17, no. 10, pp. 2735–2739, 2007.

[39] R. Studzińska, D. Kuczyk, A. Plazińska, R. Kołodziejska, T. Kosmalski, and B. Modzelewski-Banachiewicz, “Thiazolo[3,2-a]pyrimidin-5-one derivatives as a novel class of 11β-hydroxysteroid dehydrogenase inhibitors,” Bioorganic Chemistry, vol. 81, pp. 21–26, 2018.

[40] G. Navarrete-Vázquez, M. G. Morales-Vilchis, S. Estrada-Soto et al., “Synthesis of 2-2-[α/β-naphthalen-1-ylsulfonyl]amino]-1,3-thiazol-4-yl acetamides with 11β-hydroxysteroid dehydrogenase inhibition and in combo antidiabetic activities,” European Journal of Medicinal Chemistry, vol. 74, pp. 179–186, 2014.

[41] R. Studzińska, R. Kołodziejska, D. Kuczyk, W. Plaziński, and T. Kosmalski, “A novel derivatives of thiazol-4(3H)-one and their activity in the inhibition of 11β-hydroxysteroid dehydrogenase type I,” Bioorganic Chemistry, vol. 79, pp. 115–121, 2018.

[42] J. S. Scott, F. W. Goldberg, and A. V. Turnbull, “Medicinal chemistry of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1),” Journal of Medicinal Chemistry, vol. 57, no. 11, pp. 4466–4486, 2014.

[43] D. J. St. Jean Jr., C. Yuan, E. A. Bercot et al., “2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11β-hydroxysteroid dehydrogenase type I,” Journal of Medicinal Chemistry, vol. 50, no. 3, pp. 429–432, 2007.

[44] L. Johansson, C. Fotsch, M. D. Bartberger et al., “2-Amino-1,3-thiazol-4(5H)-ones as potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitors: Enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice,” Journal of Medicinal Chemistry, vol. 51, no. 10, pp. 2933–2943, 2008.

[45] M. M. Véniant, C. Hale, R. W. Hungate et al., “Discovery of a potent, orally active 11β-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: Identification of (S)-2-((1 S,2 S,4 R)-Bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5 H)-one (AMG 221),” Journal of Medicinal Chemistry, vol. 53, no. 11, pp. 4481–4487, 2010.

[46] C. Yuan, D. J. St. Jean Jr., Q. Liu et al., “The discovery of 2-anilinothiazolones as 11β-HSD1 inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 22, pp. 6056–6061, 2007.

[47] "PASS on line," http://www.pharmaexpert.ru/passonline, 2017.